Caris Life Sciences (NASDAQ: CAI) announced that its common stock will be dual-listed on NYSE Texas effective June 17, 2026, while continuing to trade on the NASDAQ as its primary exchange. The stock will carry the same CAI ticker symbol on both exchanges.

The Irving, Texas-based company said the dual listing is intended to provide additional exposure to investors, particularly within Texas and the broader U.S. market.

"Establishing a dual listing on NYSE Texas reflects both our continued growth as a public company and our deep roots in Texas, including our headquarters and over 450 Caris employees in the state," said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences.

Lynn Martin, President of NYSE Group, said the exchange was "proud to welcome Caris Life Sciences to NYSE Texas," citing the company's presence in the state.

Caris develops molecular profiling solutions using Whole Genome, Whole Exome Sequencing and Whole Transcriptome Sequencing, supported by cloud computing and artificial intelligence. The company has offices in Phoenix, New York, Cambridge (MA), Tokyo, and Basel, Switzerland, and provides services in the U.S. and international markets.